|
1
|
Li MN, Li X, He ZC and Zhang ZH:
Association between gene mutations of epidermal growth factor
receptor and clinicopathological characteristics of non-small cell
lung cancers. J Clin Exp Pathol. 29:402–405. 2013.
|
|
2
|
da Cunha Santos G, Shepherd FA and Tsao
MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang GH, Du J, Hou XH, et al: A clinical
pathology study between the different differentiation of non-small
cell lung cancer (NSCLC) and the mutation of EGFR gene. Mol Diagn
Ther. 6:97–100. 2014.
|
|
4
|
Li H, Pan Y, Li Y, et al: Frequency of
well-identified oncogenic driver mutations in lung adenocarcinoma
of smokers varies with histological subtypes and graduated smoking
dose. Lung Cancer. 79:8–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boch C, Kollmeier J, Roth A,
Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T:
The frequency of EGFR and KRAS mutations in non-small cell lung
cancer (NSCLC): Routine screening data for central Europe from a
cohort study. BMJ Open. 3:1–6. 2013. View Article : Google Scholar
|
|
6
|
Liu N, Zhang K, Yan SX, et al: EGFR
mutations are closely associated with gefitinib response in
non-small cell lung cancer patients. Modern Oncology. 21:330–333.
2013.
|
|
7
|
Zhang YS, He YY, Li XF, et al: Clinical
analysis of factors influencing EGFR mutation status in patients
with non-small cell lung cancer. Tumor. 34:147–152. 2014.
|
|
8
|
Yu H, Huang X, Zhu Z, Hu Y, Ou W, Zhang L
and Zhou N: Significance of combined detection of LunX mRNA and
tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res.
26:89–94. 2014.PubMed/NCBI
|
|
9
|
Wang WJ, Tao Z, Gu W and Sun LH: Clinical
observations on the association between diagnosis of lung cancer
and serum tumor markers in combination. Asian Pac J Cancer Prev.
14:4369–4371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cedrés S, Nuñez I, Longo M, Martinez P,
Checa E, Torrejón D and Felip E: Serum tumor markers CEA,
CYFRA21-1, and CA-125 are associated with worse prognosis in
advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer.
12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou JX, Yang H, Deng Q, et al: Oncogenic
driver mutations in patients with non-small-cell lung cancer at
various clinical stages. Ann Oncol. 24:1319–1325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Q and Li DQ: Epidermal growth factor
receptor and alveolar epithelial atypical adenomatous hyperplasia.
Int J Pathol Clin Med. 32:84–87. 2012.
|
|
13
|
Schneider CP, Heigener D, Schott-von-Römer
K, et al: Epidermal growth factor receptor-related tumor markers
and clinical outcomes with erlotinib in non-small cell lung cancer:
An analysis of patients from German centers in the TRUST study. J
Thorac Oncol. 3:1446–1453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Shi SS, Ma HH, et al: Respective
analysis of EGFR mutations in non-small cell lung cancer. Mil Med J
Southeast China. 14:387–389. 2012.
|
|
15
|
Zhao J, Zhu Y, Zhang L, Yu YW and Zheng
JM: Detection of epidermal growth factor receptor gene mutations
and its clinical significance in non-small cell lung cancers. Chin
J Pathol. 40:671–674. 2011.(In Chinese).
|
|
16
|
Sriuranpong V, Chantranuwat C, Huapai N,
Chalermchai T, Leungtaweeboon K, Lertsanguansinchai P, Voravud N
and Mutirangura A: High frequency of mutation of epidermal growth
factor receptor in lung adenocarcinoma in Thailand. Cancer Lett.
239:292–297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi S, Canepa HM, Bailey AS,
Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB:
Compound EGFR mutations and response to EGFR tyrosine kinase
inhibitors. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hata A, Yoshioka H, Fujita S, et al:
Complex mutations in the epidermal growth factor receptor gene in
non-small cell lung cancer. J Thorac Oncol. 5:1524–1528. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Zandwijk N, Mathy A, Boerrigter L,
Ruijter H, Tielen I, de Jong D, Baas P, Burgers S and Nederlof P:
EGFR and KRAS mutations as criteria for treatment with tyrosine
kinase inhibitors: Retro- and prospective observations in
non-small-cell lung cancer. Ann Oncol. 18:99–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boldrini L, Alì G, Gisfredi S, et al:
Epidermal growth factor receptor and K-RAS mutations in 411 lung
adenocarcinoma: A population-based prospective study. Oncol Rep.
22:683–691. 2009.PubMed/NCBI
|
|
21
|
Wu YL, Zhong WZ, Li LY, et al: Epidermal
growth factor receptor mutations and their correlation with
gefitinib therapy in patients with non-small cell lung cancer: A
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu CQ, da Cunha Santos G, Ding K, et al:
National Cancer Institute of Canada Clinical Trials Group Study
BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib
in National Cancer Institute of Canada Clinical Trials Group Study
BR.21. J Clin Oncol. 26:4268–4275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Zheng MF, Zhang J, Zhu XF, Chen R,
Lu R, Wo B and Chen J: EGFR Mutations in correlation with the tumor
markers in NSCLC patients. J Med Res. 40:79–81. 2011.
|
|
24
|
Shoji F, Yoshino I, Yano T, Kometani T,
Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H and Maehara Y:
Serum carcinoembryonic antigen level is associated with epidermal
growth factor receptor mutations in recurrent lung adenocarcinomas.
Cancer. 110:2793–2798. 2007. View Article : Google Scholar : PubMed/NCBI
|
